NCT00215501View on ClinicalTrials.gov

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2008

Conditions
Solid Tumor
Interventions
DRUG

Capecitabine

Orally twice a day for 14 days (dosage will vary)

DRUG

5-Fluorouracil (5-FU)

Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary

DRUG

Irinotecan

Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period

DRUG

Cisplatin

Intravenously weekly for 2 weeks followed by a one week rest period

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00215501 - Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter